Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Pierre Borczuk who wrote (4848)	8/11/1998 8:44:00 AM
From: Dave	Read Replies (1) \| Respond to of 9523

Pierre, I agree that many patients cannot tolerate NSAIDs because of their associated gastropathy and nephropathy. However, any physician worth their salt would be crazy to use a DMARD in place of an NSAID for an OA patient. Because the etiology of OA is less likely to be inflammatory (except during flares), DMARDs are of little use in OA. Additionally, their side effects are much more significant than those seen with NSAIDs. Until the COX-2 inhibitors are available, the best alternatives to COX-1 NSAIDs are non-NSAID analgesics such as acetaminophen and tramadol. Both are effective in controlling the pain of OA without the side effects seen with the NSAIDs. Regards, Dave